Company Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally.
Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies.
In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.
The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010.
Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1997 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 129 |
| CEO | Phillip Chan |
Contact Details
Address: 305 College Road East Princeton, New Jersey 08540 United States | |
| Phone | 732 329 8885 |
| Website | cytosorbents.com |
Stock Details
| Ticker Symbol | CTSO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001175151 |
| CUSIP Number | 23283X206 |
| ISIN Number | US23283X2062 |
| Employer ID | 98-0373793 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Phillip P. Chan M.D., Ph.D. | Chief Executive Officer and Director |
| Vincent J. Capponi M.S. | President and Chief Operating Officer |
| Peter J. Mariani CPA | Chief Financial Officer |
| Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. | Chief Medical Officer |
| Dr. Christian Steiner M.D. | Executive Vice President of Sales and Marketing |
| Christopher Cramer M.B.A., M.S. | Senior Vice President of Business Development |
| Kathleen P. Bloch CPA, M.B.A. | Advisor |
| Jodi Hoover | Executive |
| Dr. Robert H. Bartlett M.D. | Co-Chairman of Cardiac Surgery Advisory Board and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2026 | 10-K/A | [Amend] Annual report |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 25, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Oct 3, 2025 | 8-K | Current Report |
| Sep 16, 2025 | 8-K | Current Report |
| Aug 20, 2025 | 8-K | Current Report |